title: In vivo confocal microscopic evaluation of corneal Langerhans cell density, and distribution and evaluation of dry eye in rheumatoid arthritis.
abstract: Corneal Langerhans cells (LCs) offer the opportunity to gain insight into the activity of the innate immunity. We examined the density and the distribution of LCs and compared the results with dry-eye parameters in rheumatoid arthritis (RA). Fifty-two RA patients with various degrees of disease activity and 24 healthy subjects were enrolled. Peripheral and central LC number and morphology were assessed with in vivo laser confocal microscopy. In addition, ocular surface disease index (OSDI), lid parallel conjunctival folds, Schirmer test, and tear break-up time (TBUT) were evaluated. The prevalence of central and peripheral LC, and the central LC morphology values (LCM) were higher than normal in RA. Within the RA group, LC prevalence and morphology were not affected by disease activity. However, patients on anti-TNF or glucocorticosteroid (GCS) therapy exhibited normal LCM, and normal central and peripheral LC density. OSDI was higher and TBUT was lower than normal in RA. The alteration of LC in RA suggests an active inflammatory process in the cornea, which may reflect an increased activation state of the innate immune system-even in inactive stages of RA and without ocular symptoms. The results also indicate ocular effects of GCS therapy in RA.
authors.affiliation: Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
authors.forename: László
authors.initials: L
authors.lastname: Marsovszky
authors.forename: Miklós D
authors.initials: MD
authors.lastname: Resch
authors.forename: János
authors.initials: J
authors.lastname: Németh
authors.forename: Gergely
authors.initials: G
authors.lastname: Toldi
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Medgyesi
authors.forename: László
authors.initials: L
authors.lastname: Kovács
authors.forename: Attila
authors.initials: A
authors.lastname: Balog
mesh_terms: D000368:Aged; D019138:Antibodies, Blocking / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D002452:Cell Count; D003315:Cornea / Q000473:pathology*; D018450:Disease Progression; D015352:Dry Eye Syndromes / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007113:Immunity, Innate; D007801:Langerhans Cells / Q000276:immunology*; D008297:Male; D018613:Microscopy, Confocal / Q000379:methods; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D019138:Antibodies, Blocking; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha